Skip to main content
Clinical Trials/NCT05908019
NCT05908019
Recruiting
Not Applicable

The Effects of Pulmonary Hypertension Web-Based Health Care Program on Symptom Management, Social Support, Activity Tolerance, and Quality of Life in Patients With Pulmonary Hypertension.

National Defense Medical Center, Taiwan1 site in 1 country100 target enrollmentMay 5, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Web-based Health Care Program
Sponsor
National Defense Medical Center, Taiwan
Enrollment
100
Locations
1
Primary Endpoint
Pulmonary Arterial Hypertension Symptom
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

Pulmonary arterial hypertension (PAH) is a chronic disease characterized by an elevation in pulmonary artery pressures and pulmonary vascular resistance. The condition most often is rarely detected, and patients frequently suffer symptoms for several years before being appropriately diagnosed. Patients with PH suffer from several symptoms, such as exertional dyspnea, fatigue, weakness, chest pain, fainting...et al. Pulmonary hypertension is an incurable and progressive disease with complex symptoms and treatments. Patients must learn to deal with their unpredictable future and manage the complex treatments associated with severe adverse effects and need significant changes in lifestyle.

Therefore, it is important to assist patients to develop the ability of symptom management.

Registry
clinicaltrials.gov
Start Date
May 5, 2023
End Date
December 31, 2024
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
National Defense Medical Center, Taiwan
Responsible Party
Principal Investigator
Principal Investigator

Miao-Yi Chen

Principal Investigator

National Defense Medical Center, Taiwan

Eligibility Criteria

Inclusion Criteria

  • At least 20 years old, diagnosed by clinical specialists as patients with pulmonary hypertension (Group1 and Group 4)
  • Clear consciousness, able to communicate in Mandarin and Taiwanese, with normal hearing
  • Those who have internet or mobile internet at home
  • Adults without mental illness
  • No alcohol or drug abusers.

Exclusion Criteria

  • critical disease

Outcomes

Primary Outcomes

Pulmonary Arterial Hypertension Symptom

Time Frame: Change from Baseline pulmonary Arterial Hypertension Symptom at six months

Pulmonary Arterial Hypertension Symptom Interference Scale, PAHSS, The 10-point Likert scale higher scores mean a worse outcome.

Secondary Outcomes

  • Pulmonary Hypertension Quality of life(Change from Baseline quality of life at six months)
  • Activity ability(Change from Baseline activity ability at six months)
  • Social support(Change from Baseline social support at six months)

Study Sites (1)

Loading locations...

Similar Trials